Murky waters: The pharmaceutical industry and psychiatrists in developing countries

Psychiatric Bulletin

Volumn 30, Issue 3, 2006, Pages 85-88

  Khan, Murad Moosa ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HYPNOTIC AGENT; NEUROLEPTIC AGENT; NOOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; VENLAFAXINE;

ARTICLE; BUDGET; DEMENTIA; DEVELOPING COUNTRY; DISTRESS SYNDROME; DRUG DEPENDENCE; DRUG INDUSTRY; DRUG MARKETING; DRUG TRAFFIC; EDUCATION PROGRAM; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INCOME; MEDICAL ETHICS; MEDICAL PRACTICE; MENTAL DISEASE; MENTAL HEALTH CARE; PAKISTAN; PHARMACEUTICAL CARE; PRESCRIPTION; PREVALENCE; PSYCHIATRIST; RESOURCE ALLOCATION; SEX DIFFERENCE; SUICIDE; SYMPTOMATOLOGY; URBAN RURAL DIFFERENCE;

EID: 33644748262     PISSN: 09556036     EISSN: None     Source Type: Journal    
DOI: 10.1192/pb.30.3.85     Document Type: Article

References (16)

1. ALI, B. S., RAHBAR, M. H., NAEEM, S., et al (2003) The effectiveness of counseling on anxiety and depression by minimally trained counselors. American Journal of Psychotherapy, 57, 324-336.
2. BOLTON, P., BASS, J., NEUGEBAUER, R., et al (2003) Group interpersonal psychotherapy for depression in rural Uganda: a randomized controlled trial. Journal of the American Medical Association, 289, 3117-3124.
3. HUSSAIN, N., CHAUDHRY, I., ASFAR, S., et al (2004) Psychological distress among patients attending a general medical outpatient clinic in Pakistan. General Hospital Psychiatry, 26, 277-281.
4. IMS (2004) Pakistan Pharmaceutical Index, pp. 520-532. Switzerland: IMS.
5. JUNG, P. (2002) No free lunch. Health Affairs, 21, 226-231.
6. KAWACHI, I. & CONRAD, P. (1996) Medicalization and the pharmacological treatment of blood pressure. In Contested Ground. Public Purpose and Private Interests in the Regulation of Prescription Drugs (ed. P. Davis), pp. 26-41. NewYork: Oxford University Press.
7. KHAN, M. M. (2004) Pharmaceutical firms and doctors. The Dawn, 16 December 2004. http://www.dawn.com/2004/12/16/letted.htm#6
8. KHAN, M. M. & PRINCE, M. (2003) Beyond rates: the tragedy of suicide in Pakistan. Tropical Doctor, 331, 67-69.
9. MOYNIHAN, R., HEATH, I. & HENRY, D. (2002) Selling sickness: the pharmaceutical industry and disease mongering. BMJ, 324, 886-891.
10. MUMFORD, D. B., BAVINGTON, J.T., BHATNAGAR, K. S., et al (1991) The Bradford Somatic Inventory. A multi-ethnic inventory of somatic symptoms reported by anxious and depressed patients in Britain and the Indo-Pakistan subcontinent. British Journal of Psychiatry, 158, 379-386.
11. MUMFORD, D. B., MINHAS, F. A., AKHTER, I., et al (2000) Stress and psychiatric disorder in urban Rawalpindi: Community survey. British Journal of Psychiatry, 177, 557-562.
12. PATEL, V. & KLEINMAN, A. (2003) Poverty and common mental disorders in developing countries. Bulletin of the World Health Organization, 81, 609-615.
13. PILGRIM, D. & BENTALL, R. (1999) The medicalisation of misery: a critical realist analysis of the concept of depression. Journal of Mental Health, 8, 261-274.
14. WAZANA, A. (2000) Physicians and the pharmaceutical industry. Is a gift ever just a gift? Journal of the American Medical Association, 283, 373-380.
15. WILLIAMS, R. (2002) Drug reps are marketers, period. Health Affairs, 21, 429-4298.
16. WORLD HEALTH ORGANIZATION (1993) Clinical Pharmacological Evaluation in Drug Control. Copenhagen: WHO.